TELO
Telomir Pharmaceuticals, Inc. Common Stock NASDAQ Listed Apr 9, 2019$1.24
Pre-mkt
$1.25
+0.65%
Mkt Cap $85.3M
52w Low $0.89
29.3% of range
52w High $2.09
50d MA $1.16
200d MA $1.27
P/E (TTM)
—
EV/EBITDA
—
P/B
6.6x
Debt/Equity
0.0x
ROE
-176.1%
P/FCF
-10.6x
RSI (14)
66.70
ATR (14)
$0.07
Beta
-0.73
50d MA
$1.16
200d MA
$1.27
Avg Volume
67.3K
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
855 N Wolfe Street · Baltimore, FL 21205 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | AMC | -0.07 | -0.06 | +14.3% | 1.35 | -2.2% | -5.9% | +3.9% | +0.0% | -3.0% | +0.0% | — |
| Nov 10, 2025 | AMC | -0.07 | -0.03 | +57.1% | 1.37 | -2.2% | +3.6% | -4.9% | -3.7% | +3.8% | +3.7% | — |
| Aug 14, 2025 | AMC | -0.08 | -0.17 | -112.5% | 1.57 | -3.2% | -5.1% | +0.0% | -1.3% | -1.4% | +3.4% | — |
| May 14, 2025 | AMC | -0.10 | -0.07 | +30.0% | 2.66 | +0.4% | -11.3% | +5.9% | +1.6% | -9.8% | -7.0% | — |
| Feb 4, 2025 | AMC | -0.05 | -0.10 | -100.0% | 4.51 | -0.2% | +3.1% | -2.8% | -3.3% | +2.3% | -2.2% | — |
| Nov 12, 2024 | AMC | -0.05 | -0.20 | -300.0% | 4.19 | -2.1% | -5.0% | -0.5% | -5.8% | -11.3% | +34.1% | — |
| Aug 13, 2024 | AMC | — | -0.05 | — | 4.49 | -5.3% | -15.1% | +6.3% | -1.5% | +52.9% | -13.6% | — |
| May 13, 2024 | AMC | — | -0.23 | — | 6.66 | +0.1% | -5.3% | -1.5% | -0.5% | -0.0% | -2.3% | — |
| Mar 29, 2024 | AMC | — | -0.32 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.06 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.05 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.02 | — | — | — | — | — | — | — | — | — |
No analyst ratings available.
No insider trades available.
8-K · 7.01
! Medium
Telomir Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Sep 17
8-K
Telomir Pharmaceuticals, Inc. -- 8-K Filing
Sep 16
8-K · 7.01
! Medium
Telomir Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Sep 14
8-K · 7.01
! Medium
Telomir Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Aug 10
8-K · 7.01
! Medium
Telomir Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Telomir Pharmaceuticals published peer-reviewed zebrafish study data demonstrating Telomir-Zn's dose-dependent improvements in diabetes markers, strengthening scientific evidence for its lead clinical program's mechanism of action.
Jun 15
8-K · 5.02
!!! Very High
Telomir Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Jun 8
8-K · 7.01
! Medium
Telomir Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Telomir Pharmaceuticals published preclinical data supporting Telomir-1's potential in Wilson's disease by demonstrating reduced oxidative stress in cellular and zebrafish models, validating their therapeutic approach.
May 20
8-K · 8.01
!! High
Telomir Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Telomir Pharmaceuticals gained FDA clearance to begin human trials of Telomir-Zn for triple-negative breast cancer, enabling a Phase 1/2 study launch in mid-2026 at a major academic institution.
Apr 30
8-K · 2.01
!!! Very High
Telomir Pharmaceuticals, Inc. -- 8-K 2.01: Acquisition Completed
Telomir completed an acquisition that could expand its pipeline and market reach, but investors should monitor integration costs and dilution from financing used in the deal.
Apr 24
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Telocare's zinc-based therapeutic (Telomir-Zn) advancement signals potential clinical progress that could expand its pipeline, making it relevant for investors tracking biotech development milestones and commercialization opportunities.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
TELO filed an 8-K indicating a material event, but the vague filing details suggest potential governance or compliance updates; investors should monitor upcoming quarterly results for business impact clarification.
Mar 31
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Telomerase Therapeutics' annual shareholder meeting occurred with a January 23, 2026 record date, though the filing lacks details on voting outcomes or executive changes that could materially impact stock performance.
Mar 27
8-K · 8.01
!! High
Telomir Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Telomir Pharmaceuticals demonstrated that its Telomir-Zn candidate reduces viable tumor cells across multiple triple-negative breast cancer models through a specific mechanism, potentially validating its oncology approach.
Feb 17
8-K · 8.01
!! High
Telomir Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Telomir Pharmaceuticals released preclinical data showing Telomir-Zn modulates cellular mechanisms related to cancer and aging through epigenetic pathways rather than cytotoxic effects, potentially broadening its therapeutic applicability.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,613,639 | $2M | Added | Jun 2026 |
| 2 | Blackrock, Inc. | 280,472 | $359K | New | Jun 2026 |
| 3 | Bank Of New York Mellon Corp | 51,454 | $67K | — | Mar 2026 |
| 4 | Northern Trust Corp | 41,844 | $54K | — | Mar 2026 |
| 5 | World Investment Advisors | 37,037 | $48K | New | Jun 2026 |
| 6 | Citadel Advisors Llc | 26,532 | $34K | New | Jun 2026 |
| 7 | Onedigital Investment Advisors Llc | 23,000 | $29K | — | Jun 2026 |
| 8 | Praetorian Wealth Management, Inc. | 20,000 | $26K | — | Jun 2026 |
| 9 | Clearstead Advisors, Llc | 12,530 | $16K | — | Mar 2026 |
| 10 | Morton Capital Management Llc/ca | 12,658 | $16K | New | Jun 2026 |
| 11 | Jane Street Group, Llc | 11,677 | $16K | Reduced | Dec 2025 |
| 12 | Northcrest Asset Manangement, Llc | 12,119 | $15K | New | Jun 2026 |
| 13 | Kestra Private Wealth Services, Llc | 11,000 | $14K | — | Mar 2026 |
| 14 | Regions Financial Corp | 10,638 | $14K | — | Jun 2026 |
| 15 | Ubs Group Ag | 9,213 | $12K | Reduced | Mar 2026 |
| 16 | Bnp Paribas Financial Markets | 206 | $268 | — | Mar 2026 |
| 17 | Jpmorgan Chase & Co | 121 | $138 | — | Mar 2026 |
| 18 | Virtu Financial Llc | 17,546 | $22 | New | Jun 2026 |
| 19 | Sbi Securities Co., Ltd. | 4 | $5 | New | Jun 2026 |
| 20 | Wealth Enhancement Advisory Services, Llc | 12,119 | — | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 113,287 | $144K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 43,817 | $57K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 30,099 | $39K | May 2026 |
| 4 | Fidelity Series Total Market Index Fund | 28,520 | $37K | May 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 18,464 | $23K | Feb 2026 |
Valuation
Market Cap
$85.3M
Enterprise Value
$32.0M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.10x
P/B
6.64x
P/S
—
P/FCF
-10.64x
EV/EBITDA
—
Shares Out
31.7M
Financials (TTM)
Revenue
$0
Net Income
-$5.9M
EBITDA
-$5.9M
Free Cash Flow
-$3.7M
Op Cash Flow
-$3.7M
EPS Basic
$-0.33
EPS Diluted
$-1.51
EPS Forward
$-0.28
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$7.3M
Total Liab.
$1.4M
Total Equity
$5.9M
Cash
$7.3M
LT Debt
$0
Book Value/Sh
$0.19
Debt/Equity
0.00x
Current Ratio
5.14
Quick Ratio
5.14
Returns & Growth
ROE
-176.1%
ROA
-141.8%
ROIC
-178.2%
Rev Growth YoY
+0.0%
EPS Growth YoY
+41.1%
Price Returns
2W
+6.9%
1M
+9.7%
3M
-3.1%
6M
-6.1%
12M
-20.5%
Technicals
52W High
$2.09
52W Low
$0.89
50d MA
$1.16
200d MA
$1.27
RSI (14)
66.70
ATR (14)
$0.07
Beta
-0.73
Avg Volume
67K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 4:25am
· Source: financialmodelingprep.com